Immunocytokines: a review of molecules in clinical development for cancer therapy
Thomas List, Dario NeriDepartment of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zurich, SwitzerlandAbstract: The concept of therapeutically enhancing the immune system’s responsiveness to tumors is long standing. Several cytokines have b...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7a4cbd9c552f43488fba4cfb8dd52d4f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Thomas List, Dario NeriDepartment of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zurich, SwitzerlandAbstract: The concept of therapeutically enhancing the immune system’s responsiveness to tumors is long standing. Several cytokines have been investigated in clinical trials for their therapeutic activity in cancer patients. However, substantial side effects and unfavorable pharmacokinetic properties have been a major drawback hampering the administration of therapeutically relevant doses. The use of recombinant antibody–cytokine fusion proteins promises to significantly enhance the therapeutic index of cytokines by targeting them to the site of disease. This review aims to provide a concise and complete overview of the preclinical data and clinical results currently available for all immunocytokines having reached clinical development.Keywords: antibodies, cytokines, preclinical |
|---|